



Pfs230 and *Pfs48/45* Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against *Plasmodium falciparum*

Susheel K. Singh^{1,2†}, Susan Thrane^{2†}, Bishwanath K. Chourasia², Karina Teelen³, Wouter Graumans³, Rianne Stoter³, Geert-Jan van Gemert³, Marga G. van de Vegte-Bolmer³, Morten A. Nielsen², Ali Salanti², Adam F. Sander², Robert W. Sauerwein³, Matthijs M. Jore^{3*} and Michael Theisen^{1,2*}

OPEN ACCESS

Edited by:

Julius Clemence Hafalla,
London School of Hygiene and
Tropical Medicine (LSHTM),
United Kingdom

Reviewed by:

Rhoel Dinglasan,
University of Florida, United States
Takafumi Tsuboi,
Ehime University, Japan

*Correspondence:

Matthijs M. Jore
Matthijs.Jore@radboudumc.nl
Michael Theisen
mth@ssi.dk

[†]These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Vaccines and Molecular Therapeutics,
a section of the journal
Frontiers in Immunology

Received: 13 December 2018

Accepted: 17 May 2019

Published: 05 June 2019

Citation:

Singh SK, Thrane S, Chourasia BK, Teelen K, Graumans W, Stoter R, van Gemert G-J, van de Vegte-Bolmer MG, Nielsen MA, Salanti A, Sander AF, Sauerwein RW, Jore MM and Theisen M (2019) *Pfs230* and *Pfs48/45* Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against *Plasmodium falciparum*. *Front. Immunol.* 10:1256. doi: 10.3389/fimmu.2019.01256

¹ Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark, ² Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology, University of Copenhagen and Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ³ Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, Netherlands

The *Plasmodium falciparum* *Pfs230* and *Pfs48/45* proteins are expressed during transmission from man to mosquito and are leading candidates for a malaria transmission blocking vaccine. Individually they generate transmission blocking (TB) antibodies in rodent models. Whether the single protein vaccines are suitable to use in field settings will primarily depend on their potency to elicit functional antibodies. We hypothesized that a combination of both proteins will be more potent than each protein individually. Therefore we designed chimeric proteins composed of fragments of both *Pfs230* and *Pfs48/45* as well as single protein fragments, and expressed these in *Lactococcus lactis*. Both the individual *Pfs230* and *Pfs48/45* fragments and chimeras elicited high levels of functional antibodies in mice. Importantly, one of the chimeric proteins elicited over threefold higher transmission blocking antibody responses than the single antigens alone. Furthermore the immunogenicity of one of the chimeras could be enhanced through coupling to a virus-like particle (VLP). Altogether these data support further clinical development of these novel constructs.

Keywords: malaria, vaccines, multivalent, transmission blocking, *Lactococcus lactis*

INTRODUCTION

The transmission of *Plasmodium falciparum* from one person to another relies on the generation of male and female gametocytes in the human host that can be picked up and spread by a mosquito. The aim of a malaria transmission blocking vaccine (MTBV) is to effectively block malaria transmission at the population level thereby contributing to malaria elimination.

Several MTBV candidates have been identified by screening monoclonal antibodies generated against *P. falciparum* mosquito stages for TB activity (1–4). Three proteins, *Pfs48/45*, *Pfs230*, and *Pfs25* are currently targeted as lead candidates for an MTBV. Of these, *Pfs48/45* and *Pfs230* are expressed in the gametocyte as it develops from stage III through V in the human host. Shortly, after being taken up by a blood-feeding mosquito, the parasite emerges from the RBC as a gamete and after a few rounds of replication motile males fertilize female gametes to form zygotes. *Pfs48/45*

is expressed on the surface of both male and female gametes where it is bound to the plasma membrane through a GPI-anchor (5) and forms a stable complex with *Pfs230* (6). Both *Pfs48/45* and *Pfs230* are important for male fertility (7).

Humans develop naturally acquired immunity against *P. falciparum* gametocytes (8–10) and antibodies against *Pfs230* and *Pfs48/45* have been associated with TB activity in some but not all immune epidemiological studies (11, 12). Recently, we demonstrated that *Pfs48/45*- and *Pfs230*-specific antibodies exhibit strong TB activity in the standard membrane feeding assay (SMFA) (13), the gold standard for assessing transmission blockade *ex vivo* (2, 14–16). Whether such antibodies act synergistically, as observed for combinations of mAbs targeting different epitopes on *Pfs48/45* (2), is not yet known.

Pfs48/45 and *Pfs230* are members of the six-cysteine (6-Cys) s48/45 protein family and contain three and fourteen 6-Cys domains respectively (17). Each 6-Cys domain contains up to six cysteine residues that are involved in intra-domain disulfide bond formation which results in conformational antibody epitopes. The C-terminal 6-Cys domain of *Pfs48/45* contains the conformational epitope I, which is targeted by the most potent TB monoclonal antibody described to date, mAb45.1 (18). We have recently used the *Lactococcus lactis* expression system for the production of the C-terminal 6-Cys domain of *Pfs48/45* (6C) as a fusion protein (R0.6C) with the N-terminal GLURP-R0 region (19, 20). The resulting fusion protein can be produced in high yields of properly folded monomeric protein which elicited high levels of TB antibodies in small rodents (19, 20). In the case of *Pfs230*, the C fragment spanning the N-terminal pro-domain and first three 6-Cys domains has been shown to elicit the most potent TB antibodies (21). The presence of three 6-Cys domains suggests that disulfide bonds may be critical for proper folding of each of these domains. Accordingly, a series of *Pfs230*-specific transmission-blocking monoclonal antibodies did not recognize reduced *Pfs230* (22). In an attempt to identify the minimal *Pfs230*-domain involved in the generation of TB antibodies, *Pfs230* constructs containing the Pro, Pro+I, Pro+I,II, and Pro+I,II,III domains were produced individually in the wheat germ cell-free system (23). Interestingly, the N-terminal Pro domain, which lacks cysteines, was sufficient to elicit complement-dependent TB activity in the SMFA, suggesting that TB antibodies may also be directed against non-conformational epitopes (23). With respect to *Pfs230*, the C-fragment was the first construct to elicit TB antibodies; however, oocyst reduction was incomplete suggesting that folding was compromised by an incorrect cysteine connectivity (21). Another construct, *Pfs230D1*, corresponding to amino acid residues 444 to 736 was produced in *Pichia pastoris* as a properly folded protein and elicited TB antibodies in rodents (24).

While clinical trials with *Pfs230D1* are ongoing (ClinicalTrials.gov Identifier: NCT02334462) and R0.6C is in early clinical development phase, we sought to identify more potent *Pfs48/45*- and *Pfs230*-based immunogens. We hypothesized that a combination of antibodies against both proteins would be more potent than against each antigen individually. Therefore we constructed chimeric proteins composed of fragments of both *Pfs230* and *Pfs48/45*,

expressed these in *L. lactis* and evaluated antibody responses in rodents. A multicomponent hybrid protein containing both *Pfs48/45* and *Pfs230* holds the potential to lower the required threshold of functional antibodies and to reduce the risk of escape mutations.

METHODS

Preparation of Constructs

Three different truncated forms of *Pfs230* from N-terminus, i.e. Pro (pro domain AA 443 to 590), Pro+I (pro domain and domain I, AA 443 to 736) and Pro+I,II,III (pro domain through domain III, AA 443 to 1132) were amplified by PCR from *P. falciparum* 3D7 DNA (GenBank accession number L08135) and cloned into the *Bgl*II restriction site of pSS5 plasmid containing N-terminus Spycatcher (25). *Pfs48/45*_{291–428} (6C) was amplified from an expression vector encoding R0.6C (19, 20) using the forward primer 5'-CCATGGATCCGAAAAAAAAGTCATACACGGA TGTA ACTTC-3' and the reverse primer 5'-CCATAGATCTT GCTGAATCTATAGTA ACTGT CATATAAGC-3'. The amplified PCR product was digested with *Bam*HI and *Bgl*II (underlined) and cloned in frame into plasmids containing the Pro or Pro+I inserts to generate Pro-6C and Pro+I-6C fusion constructs, respectively. All the constructs were verified by DNA sequencing and transformed into *L. lactis* MG1363 by electroporation for expression of recombinant proteins with 6xHis tags.

Fermentation and Protein Purification

Fermentation of *L. lactis* MG1363, containing *Pfs230* or *Pfs230*-*Pfs48/45* fusion constructs were carried out as described previously (19, 26). Briefly, cell-free culture-filtrates were concentrated five-fold and buffer exchanged into Tris buffer (50 mM Tris, 50 mM NaCl pH 8.0 supplemented with 10 mM Imidazole) using a Quix Stand Benchtop system (Hollow fiber cartridge with cutoff at 10,000 or 30,000 Da, surface area 650 cm², GE Healthcare, Sweden) followed by filtration through a Durapore filter (PVDF, 0.22 μm, Millipore) and applied to a 5 ml HisTrap HP column (GE Healthcare, Sweden). Bound protein was eluted with 500 mM Imidazole in Tris buffer pH 8.0 (50 mM Tris, 50 mM NaCl) at a flow rate of 4 ml/min. Fractions containing the desired protein were further applied to a 5 ml HiTrap Q HP column (GE Healthcare, Sweden) for purification of monomeric proteins. Bound protein was eluted through step gradient elution in Tris buffer pH 8.0 (50 mM Tris, 1 mM EDTA, 1 M NaCl) and fractions containing monomers were concentrated by a VIVA spin column with a 10 or 30 kDa cutoff (Vivascience, Germany), and kept in 50 mM Tris, 250 mM NaCl and 1 mM EDTA, pH 8.0 at –80°C until use. Immune purification for Pro-6C and Pro+I-6C was done as previously described (26). Fractions containing the desired protein were pooled and then concentrated and buffer exchanged against 50 mM Tris, 100 mM NaCl, and 1 mM EDTA, pH 8.0 and kept at –80°C until use. Fractions were analyzed by SDS-PAGE and immune blotting with mAb45.1 against *Pfs48/45* conformational epitope I. Protein concentrations were measured using a BCA kit (Thermo Fisher Scientific, USA).

Protein Characterization

Analytical size exclusion high-performance liquid chromatography (SE-HPLC) of purified fusion proteins was performed as described previously (19, 20). Briefly, 5 μ l of protein was loaded on an Agilent advance Bio SEC 300 Å, 2.7 μ m, 4.6 \times 300 mm SEC column (Agilent Technologies, GB) and eluted with a 0.1 ml/min flow of elution buffer (phosphate buffer) at room temperature. Protein standards (Sigma Aldrich) were also run using the same conditions mentioned above for sizing of the purified recombinant proteins. The amount of free cysteine residues was measured using Ellman's Reagent (Thermo Fisher Scientific, USA) following the manufacturer's instructions. A standard curve was constructed using known concentrations of free cysteine (Sigma-Aldrich, USA). Folding was determined in the mAb45.1 sandwich ELISA as described (19, 26).

Production of VLPs

SpyTag was genetically fused to the N-terminus of AP205, as previously described (27). In brief, the SpyTag peptide sequence (AHIVMVDAYKPTK) was fused to the gene sequence encoding the major AP205 coat protein (Gene ID: 956335) using a flexible linker (GSGTAGGGSGS) between the two sequences. The SpyTag-AP205 VLPs were expressed in *Escherichia coli* One Shot[®] BL21 Star[™] (DE3) cells (Thermo Fisher Scientific, USA) and purified by ultracentrifugation using an Optiprep[™] (Sigma-Aldrich, USA) gradient. For conjugation to VLPs, purified soluble Pro-6C or Pro+I-6C proteins were incubated at a molar ratio of 1:1 (VLP/antigen) in a 1xPBS buffer for 2 h at room temperature. Unbound protein was removed by dialysis against PBS using 1,000 MWCO dialysis tubing (Spectrum Labs, USA). Densitometric analysis of SDS-PAGE gels was used to estimate protein concentrations.

Dynamic Light Scattering

Uncoupled VLP, soluble proteins and proteins conjugated to VLP were adjusted to 0.5–1 mg/ml in PBS and spun at 15,000 g for 10 min. Seventy microliter sample was loaded into a disposable Eppendorf Uvette cuvette (Sigma-Aldrich, USA) and measured at 25°C on a DynoPro NanoStar (WYATT Technology, USA) equipped with a 658 nm laser. Each sample was measured 20 times and intensity-average size and percentage polydispersity (PD) was estimated using Dynamic software (Version 7.5.0).

Electron Microscopy

Pro-6C or Pro+I-6C coupled to VLP (with concentrations between 0.4 and 0.5 mg/ml based on antigen content) were incubated on carbon-coated and glow-discharged grids and negatively stained with 2% phosphotungstic acid (pH 7.4). The particles were analyzed on a CM 100 BioTWIN electron microscope with an accelerating voltage of 80 kV. Images were acquired using an Olympus Veleta camera and particle size was estimated using iTEM software.

Animals and Immunogenicity Studies

In the first experiment, groups ($n = 5$) of CD-1 mice 5–7 weeks of age (Janvier Labs, Denmark) were immunized 3 times at 3-week interval by the intramuscular injection of equimolar

amounts of immune-purified Pro-6C and the individual *Pfs*230 and *Pfs*48/45 recombinant protein constructs formulated with Alhydrogel[®] (Brenntag, Denmark) to a final concentration of 2 mg/ml Aluminum. Please note that six mice received R0.6C. Each dose contained 128 pmoles of soluble protein (equivalent to 2 μ g 6C). Serum was collected on days 14, 35, and 56. In the second experiment, groups ($n = 8$) of CD-1 mice were immunized with 64 pmoles (equivalent to 1 μ g 6C) Pro-6C or Pro+I-6C (soluble or conjugated to VLP) as described above for the first experiment. One mouse receiving Pro+I-6C was terminated due to behavioral abnormalities not related to vaccination. All animals were treated in accordance with the regulations and guidelines of the European and National authorities.

Enzyme-Linked Immunosorbent Assay (ELISA) for Antibody Response Measurement

Gametocyte extract ELISA was performed with cultured sexual stage of *Pf* NF54 parasites as previously described (26). Serum immunoglobulin (IgG) subclass levels were measured using ELISA as previously described (28). For antigen-specific ELISA, 96-well plates (Nunc MaxiSorp) were coated with 0.5 μ g/well of *Pfs*48/45-6C (25), Pro+I, or Pro+I,II,II as appropriate. Antigen-specific antibodies were detected using HRP-conjugated polyclonal goat anti-mouse IgG (Novex A16072, diluted 1:3000). Antibody midpoint titer (EC50) was calculated using sigmoidal curve fitting. One-sided analysis of variance on the log-transformed values was used to confirm that ELISA data contain essential differences. Mann-Whitney test was then used to investigate whether the chimera elicited higher levels of specific antibodies compared to individual components. *p*-Values are two-sided and quoted without adjustment for multiple testing since the significance of the chimera was the primary problem under investigation. *p*-values ≤ 0.05 were considered significant. Statistical analysis was conducted using GraphPad Prism 7 (GraphPad Software, USA).

Standard Membrane Feeding Assay (SMFA)

The biological activity of specific antisera was assessed in the SMFA as previously described (26, 29). Depending on availability, wild type *P. falciparum* NF54 gametocytes or transgenic *P. falciparum* NF54 (NF54-HGL) gametocytes expressing luciferase (29) were fed to *Anopheles stephensi* mosquitoes that were reared and maintained at Radboudumc, The Netherlands. Non-heat inactivated mice sera, and active or heat-inactivated human complement was added to the cultured material prior to feeding to mosquitoes. After 6–8 days, oocysts in 20 fed mosquitoes were counted by microscopy, or quantified in four pools of five mosquitoes (NF54-HGL) by measuring luciferase levels (29). Samples were tested in two independent SMFA experiments. Luminescence-based TRA estimates from two independent feeds with each of four pools of five mosquitoes were made using generalized linear mixed models (GLMMs) without zero-inflated negative binomial error structure (30, 31). Microscopy-based estimates from two

feeds with 20 mosquitoes each were made using GLMMs with zero-inflated negative binomial error structure (30, 31). Statistical differences between test samples were determined using General Linear Mixed Regression analysis. Statistical analyses were performed using R studio (v. 3.2.4, The R Foundation, Boston, USA). Pre-immune pooled mice serum samples were also tested in a single independent SMFA experiment (Figure S2).

Depletion of Antigen-Specific IgGs

Pfs230- and *Pfs48/45*-specific antibodies were depleted from serum using *Pfs230*-CMB (32) and R0.10C-containing columns respectively, as previously described (13). The *Pfs230*-CMB fragment contains AA 444-730 and thus covers the Pro+I fragment expressed in *L. lactis*. To test if all antigen-specific IgGs were depleted, the flow through serum (depleted serum) was tested in ELISA using plates coated with *Pfs230*-CMB or SpyC-6C as appropriate (25, 26).

RESULTS

Expression of a Multivalent *Pfs230*-*Pfs48/45* Chimera in *L. Lactis*

To test whether a multivalent vaccine targeting *Pfs48/45* and *Pfs230* is immunogenic, we generated a chimeric construct containing the Pro domain of *Pfs230* fused to the 6C fragment of *Pfs48/45* (Figure 1A). We anticipated that this Pro-6C fusion protein would express well in *L. lactis* since the *Pfs230*-Pro domain is glutamate-rich, does not contain cysteines, and is similar to the R0 domain which previously enhanced expression of properly-folded 6C in *L. lactis* (25, 26). In addition to Pro-6C, we made constructs that either contained *Pfs48/45* or *Pfs230* fragments (Figure 1A). *L. lactis* MG1363 harboring these constructs were grown in a 1L bioreactor and the respective recombinant proteins were purified from the clarified supernatant through the C-terminal His-tag by immobilized metal affinity chromatography and ion exchange chromatography (Figure 1B). As expected, protein yields decreased with increasing number of *Pfs230* domains





FIGURE 1 | Production of recombinant *Pfs230* and *Pfs48/45*. **(A)** Schematic representation of *Pfs230* constructs and *Pfs230*-*Pfs48/45* chimera. Each construct contains the SpyCatcher sequence at the N-terminus and a His-tag at the C-terminus. 6-Cys domains are shown as boxes and numbers indicate the number of cysteines. The Pro-domain does not contain cysteines. **(B)** Coomassie blue stained 4–12.5% polyacrylamide gel of conventionally purified *Pfs230* constructs and immune-purified Pro-6C chimera. Protein was loaded in each lane with (+) or without (–) DTT (10 mM). The sizes (kDa) of the molecular mass markers are indicated. **(C)** Sandwich ELISA of purified Pro-6C chimera. The antigens were captured with mAb45.1 and detected with anti-His-HRP. Immune purified R0.6C were used as a reference. X-axis is shown on a logarithmic scale.

(Table S1). Pro-6C was further immune-purified on a mAb 45.1-column to enrich for properly folded protein species (Figure 1B). The yield of immune-purified Pro-6C was 15 mg/L, similar to that of R0.6C. Conformational mAb 45.1 against the *Pfs48/45* epitope I reacted with Pro-6C and this binding was equivalent to that of immune-purified R0.6C, suggesting that they exhibit similar cysteine-connectivity (Figure 1C).

Immunogenicity of Soluble *Pfs48/45* and *Pfs230* Protein Constructs

Groups of mice were immunized 3 times at 3-week interval with equimolar amounts of Pro-6C and individual *Pfs230* and *Pfs48/45* recombinant protein constructs formulated on Alhydrogel®. We used a suboptimal antigen dose to detect differences in immunogenic properties between protein

constructs. Chimeric Pro-6C elicited significantly higher levels of gametocyte-specific antibodies than those obtained with the individual Pro domain (Mann-Whitney test, $p = 0.0079$) and levels comparable to those obtained with Pro+I, and R0.6C (Figure 2A). We found that levels of specific antibodies against the Pro and 6C domains were similar in mice immunized with Pro-6C compared to mice immunized with the individual Pro and 6C (R0.6C) antigens, suggesting that these domains do not exhibit antigenic competition (Figures 2B,C). As expected, levels of *Pfs230*-specific antibodies increased with *Pfs230* fragment length (Figure 2C). The functional activity of vaccine-induced antibodies was determined by testing pooled antisera from each group in serial dilutions in the SMFA. All proteins except the Pro domain, elicited a TB response of >80% at a 1/9 dilution. Interestingly, Pro-6C induced higher levels of functional



antibodies than the other recombinant proteins including R0.6C ($p < 0.001$) (Figure 2D), supporting further investigation of multi-component *Pfs230-Pfs48/45* vaccines.


Generation of Soluble and VLP-Based Chimeric Constructs


Next, we tested whether the potency of Pro-6C could be further increased by including the first 6-Cys domain of *Pfs230* (Pro+I-6C) (Figure 3A). The Pro+I-6C chimera was purified following the same workflow developed for Pro-6C. The yield of immune-purified Pro+I-6C was 5 mg/L, which was 3-fold lower than that of Pro-6C most likely due to the additional cysteine residues (Table S1). The folding of both chimera was similar as determined in the mAb45.1 sandwich ELISA (Figure 3B). Disulfide-bonding was confirmed by demonstrating very low levels of free thiol groups (<1%) under native conditions (data not shown). Immune purified Pro-6C and Pro+I-6C eluted as single peaks by analytical size exclusion chromatography demonstrating that they form homogeneous solutions of monomeric protein species (Figures 3C,D). Before starting *in vivo* immunogenicity studies

with both soluble constructs, we also coupled Pro-6C and Pro+I-6C to virus-like particles (VLPs) to see if this would further increase the immunogenicity of the chimeras. Both Pro-6C and Pro+I-6C contained a SpyCatcher domain allowing covalent coupling to SpyTag-decorated AP205 VLPs (25, 33). Spy-Catcher Pro-6C and Pro+I-6C coupled to SpyTag VLPs efficiently (Figure 4A) and properly folded *Pfs48/45* epitope I was retained during conjugation, as shown by western blot and mAb45.1 sandwich ELISA (Figures 4A,B). Both VLPs formed homogenous populations of non-aggregated antigen-VLP complexes as demonstrated by transmission electron microscopy (Figure 4C). Furthermore, the VLP-particles displaying Pro-6C and Pro+I-6C demonstrated a low percentage of polydispersity (<16%) measured by dynamic light scattering (DLS) experiments and an average size of 71.8 and 73.7 nm, respectively (Figure 4D).

Immunogenicity of Soluble and VLP-Based Chimeric Constructs

The immunogenicity of soluble Pro-6C and Pro+I-6C, and of Pro-6C and Pro+I-6C coupled to VLPs was assessed *in vivo*.






Groups of CD-1 mice ($n = 8$) were immunized 3 times at 3-week intervals with equimolar amounts of antigen adjuvanted on Alhydrogel[®]. Soluble Pro+I-6C elicited significantly (Mann-Whitney test, $p = 0.0079$) higher levels of *Pfs230*-specific responses than soluble Pro-6C (Figure 5A). However, this increase was not associated with higher levels of gametocyte-specific antibodies (Figure 5C), possibly due to the difference in *Pfs230*-specific antibody levels being masked by higher 6C-specific signals in the gametocyte ELISA, as observed for single antigen constructs (Figure 2A). The functional activity of pooled anti-sera from each group was then tested at serial dilutions in the SMFA. Antibodies against soluble Pro+I-6C promoted higher SMFA activity than antibodies against Pro-6C at a 1/27 dilution ($p < 0.001$) (Figure 5D), in line with the SMFA results obtained with the single domain constructs (Figure 2D). VLP display did not provide an increase in gametocyte-, *Pfs48/45*-, or *Pfs230*-specific antibodies for both Pro-6C and Pro+I-6C (Figures 5A–C). VLP-display of Pro-6C enhanced (Mann-Whitney test, $p <$

0.001) the production of functional antibodies as demonstrated in the SMFA while there was no such effect for Pro+I-6C (Figure 5D).

Functional Activity of Domain Specific Antibodies in the SMFA


To investigate the functional activity of domain-specific antibodies, pooled sera from mice immunized with soluble Pro+I-6C (no VLP) were depleted for *Pfs230*- and *Pfs48/45*-specific antibodies using affinity columns with immobilized *Pfs230* and *Pfs48/45* respectively, as previously described for human antibodies (13). Antibody depletion was confirmed by ELISA (data not shown). The functional activity of antibody-depleted sera was then tested in the SMFA in 2-fold serial dilutions in the presence of complement. Sera depleted of *Pfs230*-specific or *Pfs48/45*-specific antibodies retained transmission blocking activity at 9- and 18-fold dilutions, respectively, demonstrating that functional antibodies against both proteins are induced by the Pro+I-6C construct



(**Figure 6A**). Since the TB activity of *Pfs230*-specific antibodies depends on complement (22), depleted anti-sera were re-tested in SMFA with and without active complement. As expected, *Pfs230*-specific antibodies ($\Delta 6C$) lost their functional activity in the absence of active complement (**Figure 6B**). Since complement fixation is dependent on specific antibody subclasses (34), we determined the IgG subclass profile elicited by the Pro+I-6C formulation. The chimera elicited predominantly IgG1 antibodies, and to a lower extent IgG2a and IgG2b antibodies (**Figure S1**). Altogether, these data show that functional antibodies are generated against both domains of the chimeric construct and that *Pfs230*-specific antibodies are complement dependent.

DISCUSSION

Pfs230 and *Pfs48/45* are expressed during the *P. falciparum* sexual stages in humans and elicit antibodies which effectively prevent parasite multiplication in the infected mosquito (13). Promising *Pfs230*- and *Pfs48/45*-based MTBV candidates are currently entering clinical development individually. Here we set out to produce constructs with higher potency and to this end produced and tested chimeric proteins based on both vaccine candidates. To the best of our knowledge, this is the first study that explores a multivalent MTBV based on *Pfs230* and *Pfs48/45*. Our chimeric proteins induce antibodies that have $>80\%$ transmission reducing activity in the SMFA, which is high



enough to meet the no/go decision criterion for selection and further vaccine development (35). Overall, our data show that these chimeric proteins elicited antibodies with higher TB activity in the SMFA than the single proteins alone (Figures 2D, 5D) and are therefore attractive next generation vaccine candidates.

One concern when generating multivalent vaccines is that one of the components is immunodominant and that responses against the other component are therefore compromised (36, 37). To investigate this we tested specific antibody responses against the individual domains by ELISA and demonstrated that these are not affected when the domains are presented as part of chimeric proteins. Moreover, the depletion experiments showed that antibodies against the Pro+I- and 6C-domains are functional in the SMFA. Interestingly, the Pro+I-6C chimera elicited higher levels of functional *Pfs230*-specific antibodies than the Pro+I domain alone; sera from Pro+I immunized mice showed no TRA in the SMFA at 1/27

dilution, whereas sera depleted of 6C-specific antibodies from mice immunized with Pro+I-6C still retained 99% TRA at 1/36 dilution. This apparent difference was not reflected in levels of specific antibodies detected in the *Pfs230*-ELISA indicating that functional activity in the SMFA is not only dependent on quantity but also the quality of antibodies. Importantly, there was no difference in levels of functional antibodies against the *Pfs48/45*-6C-domain when comparing Pro+I-6C and R0.6C immunized mice suggesting that the increase in functional activity of *Pfs230*-specific antibodies is, at least in part, related to a better presentation of antibody epitopes in the *Pfs230* domain I of the Pro+I-6C chimera.

Adjuvants with the ability to enhance antigen immunogenicity are critical components of an efficacious subunit vaccine. In the case of chimeras that include *Pfs230*, it is particularly important that vaccination elicit antibodies with complement-fixing activity. Here we show that Pro+I-6C formulated on Alhydrogel[®] elicited high levels of IgG1 antibodies, but also Pro+I specific IgG2a and IgG2b antibodies in mice. Murine IgG2a and IgG2b are subclasses of IgG that bind with high affinity to human complement (34). The activation of complement may subsequently trigger lysis of gametes in the infected mosquito (22). It remains to be determined whether the Pro+I-6C chimera may also elicit complement-fixing antibodies in humans.

Both *Pfs230*- and *Pfs48/45*-based vaccine constructs are rich in cysteine and proper disulfide bond formation is critical for functional antibody responses (22, 38). Therefore, successful construction and production of chimeric proteins depend on the maintenance of conformational integrity of immunologically relevant regions of the individual domains. The mAb45.1 is a conformational mAb (2) that reacts with properly folded *Pfs48/45* but not disulphide reduced *Pfs48/45* (38). Its reactivity with the fusion proteins indicate proper cysteine connectivity of the *Pfs48/45* domain. Accordingly, our results from ELISA and immunoblotting analysis showed that the purified chimeras expressed in *L. lactis* were strongly recognized by mAb45.1 and had thus retained conformational epitope I in the *Pfs48/45*-6C domain. It was particularly encouraging that recombinant Pro+I-6C reacted with mAb45.1 since *Pfs230* domain I contains four cysteine residues which may potentially interfere with disulfide bonding of the *Pfs48/45*-6C domain. While disulphide bond studies have not been completed on the two chimera, the positive reactivity with mAb45.1, indicate that the *Pfs230* sequence does not disrupt the proper disulphide formation of the *Pfs48/45* 6C domain contained within. Correct folding was further supported by antibody depletion experiments showing that both domains of the chimeras elicited functional antibodies. The data thus demonstrate that *L. lactis* is not only suitable for expression of *Pfs48/45* fragments (19), but also for *Pfs230* fragments and fusions thereof. The immune purification of the two chimeras used here is not compliant with cGMP manufacturing since a monoclonal antibody of rat origin was used. However, a purification process based on conventional chromatographic procedures is currently being developed. Although yields and purity remain to be determined, it is likely that high product

yields can be obtained through upscaling the fermentation process which is straightforward since there is no requirement for oxygen and vigorous stirring during fermentation (39). Additionally, yields of properly folded protein species may also be increased through protein refolding processes as those developed for R0.6C (20).

In conclusion, we have produced two chimeras composed of leading vaccine candidates against the transmission stages of *P. falciparum*. Both chimera elicited high levels of functional antibodies in rodents and outperformed the corresponding individual protein fragments. Previously, rodents have been immunized with *Pfs25* administered together with either *Pfs28* or *Pfs230C* (40). In contrast to our findings for *Pfs48/45-Pfs230* chimeras, the *Pfs25*-based dual-antigen vaccines did not elicit higher levels of functional antibodies than the corresponding single antigen vaccines (40). Together these data demonstrate that additive effects can only be achieved for certain antigen combinations. Our results do not only support the use of chimeric proteins for MTBV development but also for malaria vaccine development in general (26, 28, 41, 42). Another advantage of multi-component vaccines is that the production of antibodies against multiple antigens might help reduce the spread of potential escape mutants in the population. Such escape mutants may compromise overall vaccine efficacy as exemplified with the RTS,S malaria vaccine (43). This multivalent strategy is thus conceptually attractive and will constitute a novel means toward control and eventually eradication of malaria once clinical efficacy has been demonstrated.

ETHICS STATEMENT

The animal studies were approved by the Danish Animal Experiments Inspectorate. Approval number: 2013-15-2934-00902/BES.

AUTHOR CONTRIBUTIONS

SS, ST, BC, KT, RS, WG, G-JvG, MvdV-B, and MJ: performed the experiments. ST, MN, AS, and AFS: designed the VLP constructs.

REFERENCES

- Carter R, Transmission blocking malaria vaccines. *Vaccine*. (2001) 19:2309–14. doi: 10.1016/S0264-410X(00)00521-1
- Vermeulen AN, Ponnudurai T, Beckers PJ, Verhave JP, Smits MA, Meuwissen JH. Sequential expression of antigens on sexual stages of *Plasmodium falciparum* accessible to transmission-blocking antibodies in the mosquito. *J Exp Med*. (1985) 162:1460–76. doi: 10.1084/jem.162.5.1460
- Vermeulen AN, Roeffen WF, Henderik JB, Ponnudurai T, Beckers PJ, Meuwissen JH. *Plasmodium falciparum* transmission blocking monoclonal antibodies recognize monovalently expressed epitopes. *Dev Biol Stand*. (1985) 62:91–7.
- Nikolaeva D, Draper SJ, Biswas S. Toward the development of effective transmission-blocking vaccines for malaria. *Expert Rev Vaccines*. (2015) 14:653–80. doi: 10.1586/14760584.2015.993383

SS, MT, and MJ: designed the experiments. MT, MJ, and RWS: wrote the manuscript. All authors reviewed the manuscript.

FUNDING

This work was supported by the Danish Ministry of Foreign Affairs (DFC file no.14-P01-GHA), the Danish Council for Strategic research (grant 13127) and by the European Union's Horizon 2020 research and innovation program under grant agreement No. 733273. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

ACKNOWLEDGMENTS

The authors would like to thank Tenna Jensen and Magnus Friis Søndergaard for technical assistance with protein purification and characterization and Laura Pelser, Jolanda Klaassen, Astrid Pouwelsen, and Jacqueline Kuhnen for mosquito infection and dissection work.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2019.01256/full#supplementary-material>

Figure S1 | Subclass-specific antibody responses in mice immunized with Pro+I-6C. Day 56 sera were tested for antibody reactivity on ELISA plates coated (A) Pro+I or (B) 6C. Results for individual mice are shown, and a horizontal bar represents each median value.

Figure S2 | Pre-immune mouse serum contains low intrinsic TRA. Pooled mouse serum from each group was tested at 1/9 dilution in a single SMFA experiment. TRA is the reduction of oocyst numbers compared to a serum control. Error bars represent 95% confidence intervals. TRA values below 50% have large confidence intervals and this can explain the observed variation between different groups. The mean TRA of all groups is 21% (CIs: 5.7–34.1%) demonstrating that mouse serum has low intrinsic TRA.

Table S1 | Production and quantification of *Pfs230* and *Pfs230/Pfs48/45* chimeric protein in *L. lactis*.

- Kocken CH, Jansen J, Kaan AM, Beckers PJ, Ponnudurai T, Kaslow DC, et al. Cloning and expression of the gene coding for the transmission blocking target antigen *Pfs48/45* of *Plasmodium falciparum*. *Mol Biochem Parasitol*. (1993) 61:59–68. doi: 10.1016/0166-6851(93)90158-T
- Kumar N. Target antigens of malaria transmission blocking immunity exist as a stable membrane bound complex. *Parasite Immunol*. (1987) 9:321–35. doi: 10.1111/j.1365-3024.1987.tb00511.x
- van Dijk MR, Janse CJ, Thompson J, Waters AP, Braks JA, Dodemont HJ, et al. A central role for P48/45 in malaria parasite male gamete fertility. *Cell*. (2001) 104:153–64. doi: 10.1016/S0092-8674(01)00199-4
- Drakeley CJ, Bousema JT, Akim NI, Teelen K, Roeffen W, Lensen AH, et al. Transmission-reducing immunity is inversely related to age in *Plasmodium falciparum* gametocyte carriers. *Parasite Immunol*. (2006) 28:185–90. doi: 10.1111/j.1365-3024.2005.00818.x

9. Bousema JT, Drakeley CJ, Sauerwein RW. Sexual-stage antibody responses to *P. falciparum* in endemic populations. *Curr Mol Med.* (2006) 6:223–9. doi: 10.2174/156652406776055140
10. Crompton PD, Kayala MA, Traore B, Kayentao K, Ongoiba A, Weiss GE, et al. A prospective analysis of the Ab response to *Plasmodium falciparum* before and after a malaria season by protein microarray. *Proc Natl Acad Sci USA.* (2010) 107:6958–63. doi: 10.1073/pnas.1001323107
11. Theisen M, Jore MM, Sauerwein R. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine. *Expert Rev Vaccines.* (2017) 16:329–36. doi: 10.1080/14760584.2017.1276833
12. Stone WJ, Dantzler KW, Nilsson SK, Drakeley CJ, Marti M, Bousema T, et al. Naturally acquired immunity to sexual stage *P. falciparum* parasites. *Parasitology.* (2016) 143:187–98. doi: 10.1017/S003118201501341
13. Stone WJR, Campo JJ, Ouedraogo AL, Meerstein-Kessel L, Morlais I, Da D, et al. Unravelling the immune signature of *Plasmodium falciparum* transmission-reducing immunity. *Nat Commun.* (2018) 9:558. doi: 10.1038/s41467-018-03769-w
14. Carter R, Graves PM, Keister DB, Quakyi IA. Properties of epitopes of Pfs 48/45, a target of transmission blocking monoclonal antibodies, on gametes of different isolates of *Plasmodium falciparum*. *Parasite Immunol.* (1990) 12:587–603. doi: 10.1111/j.1365-3024.1990.tb00990.x
15. Rener J, Graves PM, Carter R, Williams JL, Burkot TR. Target antigens of transmission-blocking immunity on gametes of *Plasmodium falciparum*. *J Exp Med.* (1983) 158:976–81. doi: 10.1084/jem.158.3.976
16. Ponnudurai T, Lensen AH, Van Gemert GJ, Bensink MP, Bolmer M, Meuwissen JH. Infectivity of cultured *Plasmodium falciparum* gametocytes to mosquitoes. *Parasitology.* (1989) 98(Pt 2):165–73. doi: 10.1017/S0031182000062065
17. Gerloff DL, Creasey A, Maslau S, Carter R. Structural models for the protein family characterized by gamete surface protein Pfs230 of *Plasmodium falciparum*. *Proc Natl Acad Sci USA.* (2005) 102:13598–603. doi: 10.1073/pnas.0502378102
18. Roeffen W, Teelen K, van As J, vd Vegte-Bolmer M, Eling W, Sauerwein R. *Plasmodium falciparum*: production and characterization of rat monoclonal antibodies specific for the sexual-stage Pfs48/45 antigen. *Exp Parasitol.* (2001) 97:45–9. doi: 10.1006/expr.2000.4586
19. Singh SK, Roeffen W, Andersen G, Bousema T, Christiansen M, Sauerwein R, et al. A *Plasmodium falciparum* 48/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies. *Vaccine.* (2015) 33:1981–6. doi: 10.1016/j.vaccine.2015.02.040
20. Singh SK, Roeffen W, Mistarz UH, Chourasia BK, Yang F, Rand KD, et al. Construct design, production, and characterization of *Plasmodium falciparum* 48/45 R0.6C subunit protein produced in *Lactococcus lactis* as candidate vaccine. *Microbial Cell Factories.* (2017) 16:97. doi: 10.1186/s12934-017-0710-0
21. Williamson KC, Keister DB, Muratova O, Kaslow DC. Recombinant Pfs230, a *Plasmodium falciparum* gametocyte protein, induces antisera that reduce the infectivity of *Plasmodium falciparum* to mosquitoes. *Mol Biochem Parasitol.* (1995) 75:33–42. doi: 10.1016/0166-6851(95)02507-3
22. Read D, Lensen AH, Begarnie S, Haley S, Raza A, Carter R. Transmission-blocking antibodies against multiple, non-variant target epitopes of the *Plasmodium falciparum* gamete surface antigen Pfs230 are all complement-fixing. *Parasite Immunol.* (1994) 16:511–9. doi: 10.1111/j.1365-3024.1994.tb00305.x
23. Tachibana M, Wu Y, Iriko H, Muratova O, MacDonald NJ, Sattabongkot J, et al. N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-dependent malaria transmission-blocking activity. *Clin Vaccine Immunol.* (2011) 18:1343–50. doi: 10.1128/CVI.05104-11
24. MacDonald NJ, Nguyen V, Shimp R, Reiter K, Herrera R, Burkhardt M, et al. Structural and immunological characterization of recombinant 6-cysteine domains of the *Plasmodium falciparum* sexual stage protein Pfs230. *J Biol Chem.* (2016) 291:19913–22. doi: 10.1074/jbc.M116.732305
25. Singh SK, Thrane S, Janitzek CM, Nielsen MA, Theander TG, Theisen M, et al. Improving the malaria transmission-blocking activity of a *Plasmodium falciparum* 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display. *Vaccine.* (2017) 35:3726–32. doi: 10.1016/j.vaccine.2017.05.054
26. Theisen M, Roeffen W, Singh SK, Andersen G, Amoah L, van de Vegte-Bolmer M, et al. A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. *Vaccine.* (2014) 32:2623–30. doi: 10.1016/j.vaccine.2014.03.020
27. Thrane S, Janitzek CM, Matondo S, Resende M, Gustavsson T, de Jongh WA, et al. Bacterial superglue enables easy development of efficient virus-like particle based vaccines. *J Nanobiotechnol.* (2016) 14:30. doi: 10.1186/s12951-016-0181-1
28. Lousada-Dietrich S, Jogdand PS, Jepsen S, Pinto VV, Ditlev SB, Christiansen M, et al. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2—a GLURP-MSP3 fusion protein malaria vaccine candidate. *Vaccine.* (2011) 29:3284–92. doi: 10.1016/j.vaccine.2011.02.022
29. Vos MW, Stone WJ, Koolen KM, van Gemert GJ, van Schaijk B, Leroy D, et al. A semi-automated luminescence based standard membrane feeding assay identifies novel small molecules that inhibit transmission of malaria parasites by mosquitoes. *Sci Rep.* (2015) 5:18704. doi: 10.1038/srep18704
30. Churcher TS, Blagborough AM, Delves M, Ramakrishnan C, Kapulu MC, Williams AR, et al. Measuring the blockade of malaria transmission—an analysis of the standard membrane feeding assay. *Int J Parasitol.* (2012) 42:1037–44. doi: 10.1016/j.ijpara.2012.09.002
31. Bolker BM, Brooks ME, Clark CJ, Geange SW, Poulsen JR, Stevens MH, et al. Generalized linear mixed models: a practical guide for ecology and evolution. *Trends Ecol Evol.* (2009) 24:127–35. doi: 10.1016/j.tree.2008.10.008
32. Farrance CE, Rhee A, Jones RM, Musiyshuk K, Shamloul M, Sharma S, et al. A plant-produced Pfs230 vaccine candidate blocks transmission of *Plasmodium falciparum*. *Clin Vaccine Immunol.* (2011) 18:1351–7. doi: 10.1128/CVI.05105-11
33. Veggiani G, Zakeri B, Howarth M. Superglue from bacteria: unbreakable bridges for protein nanotechnology. *Trends Biotechnol.* (2014) 32:506–12. doi: 10.1016/j.tibtech.2014.08.001
34. Stewart WW, Johnson A, Stewart MW, Whaley K, Kerr MA. The activation of C3 and C4 in human serum by immune complexes containing mouse monoclonal antibodies of different isotype and affinity: effects on solubilisation. *Mol Immunol.* (1988) 25:1355–61.
35. Sauerwein RW, Bousema T. Transmission blocking malaria vaccines: assays and candidates in clinical development. *Vaccine.* (2015) 33:7476–82. doi: 10.1016/j.vaccine.2015.08.073
36. Theisen M, Cox G, Hogh B, Jepsen S, Vuust J. Immunogenicity of the *Plasmodium falciparum* glutamate-rich protein expressed by vaccinia virus. *Infect Immun.* (1994) 62:3270–5.
37. Johansson BE, Kilbourne ED. Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. *J Virol.* (1993) 67:5721–3.
38. Outchkourov N, Vermunt A, Jansen J, Kaan A, Roeffen W, Teelen K, et al. Epitope analysis of the malaria surface antigen pfs48/45 identifies a subdomain that elicits transmission blocking antibodies. *J Biol Chem.* (2007) 282:17148–56. doi: 10.1074/jbc.M700948200
39. Singh SK, Tiendrebeogo RW, Chourasia BK, Kana IH, Singh S, Theisen M. *Lactococcus lactis* provides an efficient platform for production of disulfide-rich recombinant proteins from *Plasmodium falciparum*. *Microbial Cell Factories.* (2018) 17:55. doi: 10.1186/s12934-018-0902-2
40. Menon V, Kapulu MC, Taylor I, Jewell K, Li Y, Hill F, et al. Assessment of antibodies induced by multivalent transmission-blocking malaria

- vaccines. *Front Immunol.* (2017) 8:1998. doi: 10.3389/fimmu.2017.01998
41. Pan W, Huang D, Zhang Q, Qu L, Zhang D, Zhang X, et al. Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth *in vitro*. *J Immunol.* (2004) 172:6167–74. doi: 10.4049/jimmunol.172.10.6167
 42. Kalra A, Edula JR, Gupta PK, Pandey AK, Chauhan VS. Antigenicity of a bacterially expressed triple chimeric antigen of *Plasmodium falciparum* AARP, MSP-311 and MSP-119: PfAMSP-Fu35. *PLoS ONE.* (2016) 11:e0165720. doi: 10.1371/journal.pone.0165720
 43. Neafsey DE, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A, et al. Genetic diversity and protective efficacy of the RTS,S/AS01 malaria vaccine. *N Engl J Med.* (2015) 373:2025–37. doi: 10.1056/NEJMoa1505819

Conflict of Interest Statement: A patent application covering the VLP spy-technology has been filed by the University of Copenhagen.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Singh, Thrane, Chourasia, Teelen, Graumans, Stoter, van Gemert, van de Vegte-Bolmer, Nielsen, Salanti, Sander, Sauerwein, Jore and Theisen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.